Positive top-line Phase III data for ViiV Healthcare 's second two-drug HIV product, a combination of Tivicay (dolutegravir) and the older anti-HIV drug Epivir (lamivudine), still leave experts wanting to see key details on virological failures observed in the two trials, GEMINI 1 & 2, particularly whether there is a trend for a higher rate of virologic failure in patients with high baseline viral loads (HIV RNA >100,000 copies/mL).
The studies, which compared Tivicay/Epivir to a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors, tenofovir disoproxil fumarate/emtricitabine...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)